Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 09:12 am Sale |
2023-12-31 | 13G | Biotech Acquisition Company BIOT |
Radcliffe Capital Management L.P. | 0 0.000% |
-405,900 (Position Closed) |
Filing History |
| 2023-02-14 10:50 am Sale |
2022-12-30 | 13G | Biotech Acquisition Company BIOT |
GOLDMAN SACHS GROUP INC GS |
250,525 1.100% |
-944,153 (-79.03%) |
Filing History |
| 2023-02-14 10:35 am Purchase |
2022-12-31 | 13G | Biotech Acquisition Company BIOT |
Glazer Capital, LLC | 2,283,910 9.930% |
2,283,910 (New Position) |
Filing History |
| 2023-02-13 3:47 pm Sale |
2022-12-31 | 13G | Biotech Acquisition Company BIOT |
Beryl Capital Management LLC | 0 0.000% |
-2,039,377 (Position Closed) |
Filing History |
| 2023-02-13 2:11 pm Purchase |
2022-12-31 | 13G | Biotech Acquisition Company BIOT |
ARISTEIA CAPITAL LLC | 1,524,010 6.630% |
375,000 (+32.64%) |
Filing History |
| 2023-01-27 1:18 pm Purchase |
2023-01-25 | 13G | Biotech Acquisition Company BIOT |
Radcliffe Capital Management L.P. | 405,900 5.390% |
405,900 (New Position) |
Filing History |
| 2023-01-25 12:12 pm Purchase |
2022-12-31 | 13G | Biotech Acquisition Company BIOT |
Hudson Bay Capital Management LP | 1,261,609 5.490% |
1,261,609 (New Position) |
Filing History |
| 2022-05-16 4:37 pm Purchase |
2022-05-06 | 13G | Biotech Acquisition Company BIOT |
Beryl Capital Management LLC | 2,039,377 8.900% |
2,039,377 (New Position) |
Filing History |
| 2022-02-14 4:01 pm Purchase |
2021-12-31 | 13G | Biotech Acquisition Company BIOT |
Biotech Sponsor LLC | 5,750,000 20.000% |
5,750,000 (New Position) |
Filing History |
| 2022-02-14 2:08 pm Sale |
2021-12-31 | 13G | Biotech Acquisition Company BIOTU |
Atalaya Capital Management LP | 928,125 4.000% |
-556,875 (-37.50%) |
Filing History |
| 2022-02-14 08:44 am Purchase |
2021-12-31 | 13G | Biotech Acquisition Company BIOT |
ARISTEIA CAPITAL LLC | 1,149,010 5.000% |
1,149,010 (New Position) |
Filing History |
| 2022-02-10 12:29 pm Purchase |
2021-12-31 | 13G | Biotech Acquisition Company BIOT |
GOLDMAN SACHS GROUP INC GS |
1,194,678 5.200% |
1,194,678 (New Position) |
Filing History |
| 2021-12-14 4:22 pm Unchanged |
2021-10-01 | 13G | Biotech Acquisition Company BIOTU |
Atalaya Capital Management LP | 1,485,000 6.500% |
0 (Unchanged) |
Filing History |
| 2021-02-16 5:07 pm Purchase |
2021-01-28 | 13G | Biotech Acquisition Company BIOTU |
Vellar Opportunities Fund Master Ltd. | 1,500,000 6.500% |
1,500,000 (New Position) |
Filing History |
| 2021-02-05 4:26 pm Purchase |
2021-01-26 | 13G | Biotech Acquisition Company BIOTU |
Atalaya Capital Management LP | 1,485,000 6.500% |
1,485,000 (New Position) |
Filing History |